Display options
Cite
Włodarczyk J, Włodarczyk M, Zielińska M, et al. Blockade of fructose transporter protein GLUT5 inhibits proliferation of colon cancer cells: proof of concept for a new class of anti-tumor therapeutics. Pharmacol Rep. 2021;73(3):939-945doi: 10.1007/s43440-021-00281-9.
Włodarczyk, J., Włodarczyk, M., Zielińska, M., Jędrzejczak, B., Dziki, �. �., & Fichna, J. (2021). Blockade of fructose transporter protein GLUT5 inhibits proliferation of colon cancer cells: proof of concept for a new class of anti-tumor therapeutics. Pharmacological reports : PR, 73(3), 939-945. https://doi.org/10.1007/s43440-021-00281-9
Włodarczyk, Jakub, et al. "Blockade of fructose transporter protein GLUT5 inhibits proliferation of colon cancer cells: proof of concept for a new class of anti-tumor therapeutics." Pharmacological reports : PR vol. 73,3 (2021): 939-945. doi: https://doi.org/10.1007/s43440-021-00281-9
Włodarczyk J, Włodarczyk M, Zielińska M, Jędrzejczak B, Dziki Ł, Fichna J. Blockade of fructose transporter protein GLUT5 inhibits proliferation of colon cancer cells: proof of concept for a new class of anti-tumor therapeutics. Pharmacol Rep. 2021 Jun;73(3):939-945. doi: 10.1007/s43440-021-00281-9. Epub 2021 May 29. PMID: 34052986; PMCID: PMC8180478.
Copy Download .nbib Format: NLM
Share it on

Pharmacol Rep. 2021 Jun;73(3):939-945. doi: 10.1007/s43440-021-00281-9. Epub 2021 May 29.

Blockade of fructose transporter protein GLUT5 inhibits proliferation of colon cancer cells: proof of concept for a new class of anti-tumor therapeutics.

Pharmacological reports : PR

Jakub Włodarczyk, Marcin Włodarczyk, Marta Zielińska, Bartłomiej Jędrzejczak, Łukasz Dziki, Jakub Fichna

Affiliations

  1. Department of Biochemistry, Medical University of Lodz, Mazowiecka 6/8, 92-215, Lodz, Poland. [email protected].
  2. Department of General and Colorectal Surgery, Medical University of Lodz, ?eromskiego 113, 90-549, Lodz, Poland.
  3. Department of Biochemistry, Medical University of Lodz, Mazowiecka 6/8, 92-215, Lodz, Poland.

PMID: 34052986 PMCID: PMC8180478 DOI: 10.1007/s43440-021-00281-9

Abstract

BACKGROUND: Despite the fact that colorectal cancer (CRC) is one of the most commonly diagnosed cancers in men and women, its current treatment remains unsatisfactory and therefore novel studies proposing new approaches are necessary. A high sugar diet is believed to promote carcinogenesis. Fructose is absorbed from the gastrointestinal tract by members of the glucose transporter family-GLUT. The aim of the study was to characterize the expression of GLUT5 at mRNA level in CRC patients. Moreover, our goal was to elucidate the molecular role of GLUT5 in CRC and assess whether GLUT5 inhibitor may affect the viability of colon cancer cells.

METHODS: The expression of GLUT5 at mRNA level was characterized based on 30 samples from resected colorectal cancers and 30 healthy colonic mucosa specimens from surgical margins. The inhibitory effect of N-[4-(methylsulfonyl)-2-nitrophenyl]-1,3-benzodioxol-5-amine (MSBNA) was assessed on a colon cancer cell line, HT-29, and normal colon epithelium cells-CCD 841 CoN Cells.

RESULTS: GLUT5 expression was found in 96.7% of cancer specimens and only in 53.3% of healthy mucosa fragments. In cancer tissue, real-time PCR analysis showed almost 2, fivefold (p< 0.001) increase of GLUT5 mRNA expression level compared with the healthy intestinal mucosa. GLUT5 inhibitor, MSNBA (10 µM) significantly decreased the viability of colon cancer cells, while barely affected the viability of normal colon epithelium cells.

CONCLUSIONS: Our study suggests that a strong focus should be put on GLUT5 and its inhibitors for both diagnostic and therapeutic purposes in CRC.

Keywords: Colorectal cancer; Fructose; GLUT5; N-[4-(methylsulfonyl)-2-nitrophenyl]-1,3-benzodioxol-5-amine

References

  1. CA Cancer J Clin. 2011 Jul-Aug;61(4):212-36 - PubMed
  2. Int J Cancer. 2015 Mar 1;136(5):E359-86 - PubMed
  3. World J Gastroenterol. 2018 Feb 21;24(7):775-793 - PubMed
  4. Cell Death Discov. 2018 Feb 26;4:38 - PubMed
  5. Genes Dis. 2019 Oct 16;7(2):163-165 - PubMed
  6. Nat Chem Biol. 2017 Nov;13(11):1158-1163 - PubMed
  7. J Behav Med. 2014 Aug;37(4):698-708 - PubMed
  8. Signal Transduct Target Ther. 2020 Mar 20;5(1):22 - PubMed
  9. Am J Physiol Endocrinol Metab. 2008 Aug;295(2):E227-37 - PubMed
  10. Sci Rep. 2019 Jun 26;9(1):9299 - PubMed
  11. Science. 2019 Mar 22;363(6433):1345-1349 - PubMed
  12. Pflugers Arch. 2020 Sep;472(9):1207-1248 - PubMed
  13. Curr Opin Endocrinol Diabetes Obes. 2012 Oct;19(5):367-74 - PubMed
  14. Carcinogenesis. 2020 Oct 15;41(10):1329-1340 - PubMed
  15. J Cell Physiol. 2006 Jun;207(3):614-27 - PubMed
  16. Cancer Metab. 2020 Jul 10;8:16 - PubMed
  17. Oncol Rep. 2011 Feb;25(2):315-23 - PubMed
  18. Lancet. 2014 Apr 26;383(9927):1490-1502 - PubMed
  19. Horm Mol Biol Clin Investig. 2015 May;22(2):79-89 - PubMed
  20. Nat Rev Dis Primers. 2015 Nov 05;1:15065 - PubMed
  21. PeerJ. 2017 Sep 27;5:e3804 - PubMed
  22. Physiology (Bethesda). 2007 Aug;22:234-40 - PubMed
  23. Int J Cancer. 2012 Jan 1;130(1):159-69 - PubMed
  24. Sci Rep. 2016 Apr 14;6:24240 - PubMed
  25. J Physiol. 2013 Jan 15;591(2):401-14 - PubMed
  26. Ann Oncol. 2010 May;21 Suppl 5:v93-7 - PubMed
  27. Cancer Res. 2010 Aug 1;70(15):6368-76 - PubMed
  28. F1000Prime Rep. 2014 Nov 04;6:108 - PubMed
  29. Cell Death Dis. 2018 May 10;9(5):557 - PubMed

Publication Types

Grant support